Practical implication
Healthcare providers must ensure patient registrations and comply with adverse event reporting as per the renewed compassionate use framework, which includes the collection and analysis of safety data.
The ANSM has renewed the compassionate use framework (CPC) for Methotrexate, effective July 22, 2026. This renewal requires mandatory patient registration and adverse event reporting by healthcare providers. The framework will be in place for three years, with a new therapeutic use and patient monitoring protocol replacing the previous one.
What changed: The compassionate use framework for Methotrexate has been renewed, with updated protocols for patient monitoring and safety reporting obligations for a period of three years starting July 28, 2026.
Why it matters: Maintaining rigorous pharmacovigilance for off-label Methotrexate use is crucial to ensure patient safety and support ongoing evaluations of treatment risks and benefits.
Practical implication: Healthcare providers must ensure patient registrations and comply with adverse event reporting as per the renewed compassionate use framework, which includes the collection and analysis of safety data.
View original source
Published from the Firecrawl policy change extraction pipeline.
